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Tumorigenesis is a complex, multi-step process, which
includes activation of oncogenes, inactivation of tumor
suppressor genes, mutation of DNA repair genes and
other related factors [1–5]. The activation of oncogenes
and inactivation of tumor suppressor genes can be
induced by point mutation, deletions and amplifica-
tion of these genes, but also by methylation on the
promoters of these genes. It has been shown that
methylation of the CpG island in promoter regions can
inactivate genes during early cellular development
and differentiation [6–9]. Furthermore, methylation of
the CpG islands in the promoters of tumor suppressor
genes can inactivate these genes [10–17]. The Wingless
(Wnt) pathway plays key roles in embryonic devel-
opment, tissue homeostasis and carcinogenesis [8–11,
18–21]. Extracellular Wnt proteins activate membrane
receptors, which in turn mediate phosphorylation of
Dishevelled, one of the multimodule proteins working
in the Wnt pathway. Dishevelled inhibits the phospho-
rylation of β-catenin by binding Axin and disrupting
a complex consisting of the adenomatous polyposis
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The inactivation of tumor suppressor genes by promoter methylation plays an important role in
the development of cancers; it can also be used as a marker to distinguish cancerous cells from
non-cancer cells. In this study, we investigated the aberrant methylation profile of the tumor 
suppressor genes P15, P16, APC and E-cadherin in the cells of body fluid. A methylation-specific
polymerase chain reaction was performed in 31 cases of malignant effusion and 39 cases of non-
malignant effusion. Aberrant promoter methylation of P15, P16, APC and E-cadherin genes was
seen in 0%, 25.8%, 35.5% and 6.5% of malignant effusion cases, respectively, whereas the frequencies
were 0%, 2.6%, 2.6% and 0%, respectively, for negative control effusion. There were statistically sig-
nificant differences in the aberrant methylation of P16 (p=0.008) and APC (p=0.018) genes between
cases of malignant effusion and controls. Methylation of one of three genes (P16, E-cadherin,
APC) was found in 14 out of 31 (45.2%) cases of malignant effusion, and in two out of 39 (5.1%)
cases of non-malignant effusion (p = 0.000004). Concurrent methylation was found in nine out of
31 (29%) cases of malignant effusion, but in no non-malignant effusion sample. From these
results, we suggest that methylation-specific polymerase chain reaction to analyze the promoters
of tumor suppressor genes can distinguish between malignant effusion and benign effusion, and
may help cytologists to make more accurate diagnoses.
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coli (APC), Axin, and glycogen synthase 3β (GSK-3β).
Unphosphorylated β-catenin then interacts with a tran-
scriptional coactivator and T-cell factor/lymphoid-
enhancer factor (Tcf/Lef) and activates the transcription
of target genes [18–21]. The genes encoding APC,
Axin and GSK-3β are thought to be tumor suppressor
genes owing to their main function as regulators of 
β-catenin. E-cadherin has also been suggested to be 
a tumor suppressor gene. Mutation-induced suppres-
sion of E-cadherin expression has been associated
with breast cancer and familial gastric cancer [14,19].
Under physiologic conditions, most β-catenin is bound
to E-cadherin, suggesting a crucial regulatory role of
E-cadherin in the Wnt signaling pathway [20]. The
P15 and P16 genes are important tumor suppressors
through cell cycle regulation, and previous reports
have demonstrated hypermethylation of P16 and P15
in many cancers [21,22].
Cytologic examination of fluids obtained from the
serous cavities is among the most common tasks per-
formed in the practice of cytopathology. The diagnostic
utility of effusion cytology is now well established,
making it routine when trying to find the cause of
fluid accumulation in a serous cavity. The most com-
mon reason for performing cytologic examination 
of fluids is to determine whether or not it contains
malignant cells. In patients with clinically and/or
pathologically proven pleural malignancy, cytologic
examination of pleural fluid is positive in 71% of
cases. The sensitivity of cytology for the diagnosis of
malignancy is 58%. Due to the low specificity and
sensitivity of routine cytologic examination of body
fluids, especially to distinguish between benign and
malignant mesothelial cells, it greatly affects clinical
management and outcome.
Recent studies have shown that alterations in the
tumor suppressor genes P15, P16 and APC-3, and in
the adhesion molecule E-cadherin, were common in
adenocarcinomas; however, no study has performed
a concurrent analysis of the promoter methylation
status of P15, P16, APC and E-cadherin genes in body
fluids. Therefore, we used a panel of genes to aid in
the identification of an epithelial population of cells
in effusion.
MATERIALS AND METHODS
Specimens
Ascites fluid and pleural effusion were collected from
31 patients with metastatic adenocarcinomas and 39
patients with nonmalignant etiologies such as conges-
tive heart failure, liver cirrhosis and infection. Samples
were divided into two, one half for conventional cytol-
ogy examination and the other for methylation study.
This study was approved by the institutional review
board of Changhua Christian Hospital and China
Medical University Hospital.
DNA extraction, methylation PCR 
and sequencing
DNA extraction was performed as previously des-
cribed [23,24]. Sodium bisulfite modification of DNA
and methylation-specific polymerase chain reaction
(PCR) were performed as previously described [23–25],
with some modifications. The primer pairs used for the
detection of methylated and unmethylated sequences
on the promoters of various tumor-related genes are
as previously described [23,24]. Generally, approxi-
mately 4 µg of genomic DNA in 40 µL H2O was dena-
tured by incubation with 10 µL of 1 M NaOH at 37°C
for 10 minutes, and then modified by 30 µL of 10 mM
hydroquinone and 520 µL of 1.5 M sodium bisulfite
(pH 5.0) at 50°C for 16 hours. DNA samples were
eluted with 100 µL of pre-warmed H2O (65–70°C)
using the wizard DNA purification kit (Promega,
Madison, WI, USA). Then, 50 µL of 1 M NaOH was
added to the eluant and the mixture was incubated at
Table 1. Results of methylation-specific polymerase chain reaction analysis of P15, P16, APC-3 and E-cadherin genes
Malignant effusion (n = 31) Nonmalignant effusion (n = 39)
p
Methylated Unmethylated Methylated Unmethylated
P16 8 23 1 38 0.008
E-cadherin 2 29 0 39 0.193
APC-3 7 24 1 38 0.018
One of these genes 17 14 2 37 4 × 10−6
room temperature for 5 minutes. After precipitation
with 150 µL of 100% isopropanol, the precipitate was
washed with 70% ethanol. The DNA pellet was resus-
pended in 45 µL of H2O. Modified DNA pellets were
amplified in a total volume of 20µL containing 1X PCR
buffer, 1 mM MgCl2, 100 ng of each primer, 0.2 mM
dNTPs and 2.5 units of Taq polymerase. PCR was
performed in a thermal cycler for 35 cycles consisting
of denaturation at 94°C for 30 seconds, annealing at 
a specific temperature, as shown in Table 1, for 
1 minute and extension at 72°C for 1 minute, followed
by a final 5-minute extension at 72°C. PCR products
were then loaded onto 3.5% agarose gels and electro-
phoresed, stained with ethidium bromide and visual-
ized under UV illumination. CpG methylase (Sss
I)-treated genomic DNA was used as a positive con-
trol for the methylation-specific primers because Sss I
methylates all cytosines within the double-stranded
dinucleotide CG. DNA samples from healthy individu-
als that produced no PCR products with methylation-
specific primer sets, but did produce PCR products
with unmethylation-specific primer sets, were used 
as positive controls for the unmethylation-specific
primers. To ensure the specificity of methylation- 
or unmethylation-specific primer sets for bisulfite-
modified DNA, amplification using unmodified
genomic DNA samples from healthy individuals was
also performed. For some representative cases, the
PCR products were further analyzed by direct sequenc-
ing to confirm the results. Direct sequencing was per-
formed on an ABI Prism 310 Genetic Analyzer using
BigDye Terminator Cycle Sequencing Kits (Applied
Biosystems, Foster City, CA, USA).
RESULTS
The results of the methylation-specific PCR analysis
of P15, P16, APC and E-cadherin are shown in the
Figure. In total, 31 cases of malignant effusion and 39
cases of negative control effusion were analyzed for
the methylation status of P15, P16, E-cadherin and
APC (Table 1). The frequency of aberrant methyla-
tion was 0% for P15, 25.8% (8/31) for P16 (p = 0.008),
6.5% (2/31) for E-cadherin (p = 0.193) and 35.5%
(11/31) for APC (p = 0.018). In nonmalignant effusion
samples, less frequent methylation was detected in
P15 (0%), P16 (2.6%), E-cadherin (0%) and APC
(2.6%). There was a statistically significant higher 
frequency of aberrant methylation of P16 and APC
genes in malignant compared to nonmalignant effu-
sions. Methylation of one of the four genes analyzed
(P15, P16, E-cadherin, APC) was found in 14 out of 
31 (45.2%) cases of malignant effusion and two of 
39 (5.1%) cases of negative control effusion (p =
0.000004). It is suggested that any one of these genes
showing methylation in body fluid is a positive marker
for malignancy. The results of concurrent methyla-
tion of P16, E-cadherin and APC are shown in Table 2.
Of the 31 malignant effusion samples, one showed
methylation of three genes (P16, E-cadherin and APC),
two showed methylation of both P16 and E-cadherin,
two showed methylation of both E-cadherin and APC,
and four showed methylation of both APC and P16.
Nine out of the 31 (29%) malignant effusion samples
were positive for methylation changes in one of P16,
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Table 2. Number of cases showing concurrent methyla-
tion among P15, P16, E-cadherin and APC-3
Body fluid
Tumor Non-tumor
Methylation gene
All 4 genes 0 0
P16 + E-cadherin + APC-3 1 0
P16 + E-cadherin 2 0
P16 + APC-3 4 0
E-cadherin + APC-3 2 0
1M
p16
APC
E-cadherin
2 3 4 5 6 7 8 9 10 11 12 13
Figure. The results of methylation-specific polymerase chain
reaction analysis of P16, APC and E-cadherin genes are shown.
Thirteen representative cases are shown. Case 8 shows methyla-
tion of all three genes, cases 4, 5, 6 and 10 show P16 and APC
methylation, case 2 shows P16 and E-cadherin methylation, cases
1, 3, 9 and 12 show APC methylation, and cases 11 and 13 show
P16 methylation. M is the 100 bp ladder marker.
E-cadherin or APC genes. None of the 39 negative
control effusion samples showed concurrent methyl-
ation changes. Moreover, the frequency of concurrent
gene methylation may also provide a more sensitive
method for cancer detection. No methylation change in
P15 was found in either malignant effusion samples
or negative control effusions.
DISCUSSION
In the development of cancer, a number of tumor
suppressor genes are inactivated by mutations and
chromosomal deletions [26]. Aberrant methylation 
of CpG islands has been shown to serve as an alter-
native way of inactivating these genes in cancer.
Recently, concurrent CpG-island hypermethylation has
been reported in colorectal, pancreatic, gastric and
oral carcinomas [12–19,27–30]. We have analyzed the
methylation patterns of P15, P16, E-cadherin and
APC in malignant pleural effusions and ascites, and
negative control pleural effusion and ascites. Our
results showed that aberrant methylation of P15
(0%), P16 (25.8%), E-cadherin (6.5%) and APC (35.5%)
occurred in cases of malignant effusion. Nine cases 
of malignant effusion (29%) displayed concurrent
hypermethylation.
Surprisingly, we found no aberrant methylation
of P15 in either malignant or nonmalignant disor-
ders. The P15 and P16 genes are important tumor
suppressors through cell cycle regulation [21,22]. In
our results, the aberrant hypermethylation rates 
of P16 and P15 were 25.8% and 0%, respectively.
Aberrant methylation of P16 occurred frequently,
and was significantly higher in malignant effusions
than in nonmalignant effusions (p = 0.008). No aber-
rant methylation of P15 was noted in either sample;
therefore, this result suggested that methylation silenc-
ing of P15 might not be useful for the detection of
cancer in body fluids.
The Wnt signaling pathway is commonly associ-
ated with the process of colon cancer tumorigenesis.
Somatic mutations in the APC gene are present in
80% of sporadic colorectal cancers; however, 18% of
sporadic colon cancers also demonstrated promoter
methylation in 95% of the wild-type APC gene, sug-
gesting an alternative mechanism of APC inactiva-
tion in colon tumorigenesis [31–33]. In our results,
aberrant promoter methylation of the APC gene (35.5%)
was much higher than seen previously. E-cadherin 
is a transmembrane glycoprotein that forms a com-
plex with catenins, thereby linking E-cadherin to the
actin cytoskeleton. There is compelling evidence from 
in vitro and in vivo experiments to suggest that the E-
cadherin/catenin complex acts as an invasion suppres-
sor [34]. It has been reported that loss of expression of
E-cadherin by methylation of the promoter region
was observed in 54.5% of poorly differentiated ade-
nocarcinomas and mucinous carcinomas of the colon
and rectum [35]. In our study, only 6.5% of malignant
effusion cases showed aberrant promoter methylation.
This discrepancy may be due to the fact that most
(91%) of our patients had well to moderately differ-
entiated adenocarcinomas. These findings suggest that
aberrant promoter methylation of E-cadherin is not
common in malignant effusions.
In conclusion, our study demonstrated the methyl-
ation profile of body fluid through a candidate gene
approach. Our data indicated that aberrant promoter
methylation is common in some tumor suppressor
genes. The epigenetic silencing of multiple tumor
suppressor genes might be a useful biomarker for
diagnosing metastatic carcinomas in body fluids.
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